Pilot production payment for LabTech
Friday, 12 September, 2008
LabTech Systems (ASX: LBT) has sent pilot production units of its MicroStreak technology to partner bioMérieux, triggering a $1.74 million milestone payment.
LabTech Systems signed an exclusive license agreement with bioMérieux last year. The French diagnostics giant will market the technology under its PREVI Isola brand.
The technology is a high-speed robotic platform for agar plate streaking in microbiology and pathology labs.
This payment brings the total revenue from the agreement to $6.67 million.
The PREVI Isola will be on sale later this year. LabTech Systems also expects royalty payments to begin from January 1 next year.
Could this psychedelic compound reduce post-concussion symptoms?
Few effective therapies exist for concussion. Now, an Australian clinical trial is exploring...
Turning point — optimal antibiotics for golden staph bloodstream infections
Involving more than 150 hospitals across more than 14 countries, a global clinical trial supports...
Alloy implants that naturally dissolve after healing
Australian researchers have been developing biodegradable magnesium-based alloys that more...
